EUCTR2009-011454-17-FR进行中（未招募）1 期
Etude pharmacocinétique de la doxorubicine en fonction de l'âge chez des enfants atteints de tumeurs ou leucémies. - Doxo
Hôpital Universitaire de Münster0 个研究点目标入组 100 人开始时间: 2010年3月22日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients de moins de 18 ans.
- •Traités par la doxorubicine pour les tumeurs de Wilms, neuroblastome, sarcome des tissus mous, sarcome d’Ewing ou leucémie lymphoblastique aiguë, selon le protocole national ou européen du traitement de ces tumeurs.
- •Exceptionnellement, les enfants de moins de 3 ans, traités avec la doxorubicine pour d’autres types de tumeur sont inclus.
- •Espérance de vie supérieure à trois mois.
- •Consentement parental ou du représentant légal.
- •Accord de l’enfant s'il est en âge de comprendre.
- •Statut de performance de Karnofsky inférieur ou égal à 70%.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Antécédents cardiaques.
研究者
相似试验
进行中（未招募）
不适用
Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer. - AC PK StudyEarly breast cancerEUCTR2005-004126-56-GBewcastle upon Tyne Hospitals NHS Trust50
进行中（未招募）
1 期
A study investigating the pharmcokintetics (how the body processes with a drug) and pharmcodynamics (what effect the drug has on the body) of the chemotherapy drug doxorubicin, when used to treat children, adolescents and young adults with newly diagnosed cancers: osteosarcoma, Ewing's family of tumours, and Hodgkin lymphoma.Ewing family of tumoursOsteosarcomaHodgkin lymphomaMedDRA version: 14.1Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10015570Term: Ewing's tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10031291Term: OsteosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005554-62-GBAustralian Sarcoma Group (ASSG)210
已完成
不适用
Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional Cross-Discipline Non-Therapeutic StudyOsteosarcomaEwing Family of TumoursCancer - Children's - Leukaemia & LymphomaCancer - BoneCancer - Other cancer typesHodgkin LymphomaACTRN12609000956202Australasian Sarcoma Study Group79
进行中（未招募）
1 期
A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide.This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of refractory or recurrent small cell lung carcinoma after platinum derivatives and etoposide, for which no standard treatment is available in this indication.EUCTR2008-004278-41-BEInstitut Jules Bordet43
进行中（未招募）
1 期
Phase II study evaluating the combination of liposomal doxorubicin pluscyclophosphamide with trastuzumab followed by docetaxel plustrastuzumab as therapy to be performed before surgery (neoadjuvantchemotherapy) for patients with breast cancer more than 2 cm in size and possible involvement of the lymph nodes adjacent and with the receptor HER2 positive.MedDRA version: 14.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864ocal advanced breast cancer resectable, neoadjuvant settingEUCTR2013-002684-25-ITS.I.C.O.G. ONLUS41